Compare ENS & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENS | IOVA |
|---|---|---|
| Founded | 1991 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 968.6M |
| IPO Year | N/A | N/A |
| Metric | ENS | IOVA |
|---|---|---|
| Price | $149.34 | $2.86 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 12 |
| Target Price | ★ $151.33 | $10.45 |
| AVG Volume (30 Days) | 450.2K | ★ 11.3M |
| Earning Date | 02-04-2026 | 11-06-2025 |
| Dividend Yield | ★ 0.70% | N/A |
| EPS Growth | ★ 21.73 | N/A |
| EPS | ★ 8.58 | N/A |
| Revenue | ★ $3,725,304,000.00 | $250,425,000.00 |
| Revenue This Year | $4.71 | $60.71 |
| Revenue Next Year | $2.75 | $59.52 |
| P/E Ratio | $17.45 | ★ N/A |
| Revenue Growth | 6.17 | ★ 175.62 |
| 52 Week Low | $76.57 | $1.64 |
| 52 Week High | $152.01 | $8.15 |
| Indicator | ENS | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 63.06 | 69.64 |
| Support Level | $138.34 | $2.08 |
| Resistance Level | $151.37 | $2.60 |
| Average True Range (ATR) | 3.96 | 0.16 |
| MACD | -0.47 | 0.06 |
| Stochastic Oscillator | 83.61 | 90.80 |
EnerSys provides stored energy solutions for industrial applications. It also manufactures and distributes energy systems solutions and motive power batteries, specialty batteries, battery chargers, power equipment, battery accessories, and outdoor equipment enclosure solutions to customers. Energy Systems that combine enclosures, power conversion, power distribution, and energy storage are used in the telecommunication and broadband, utility industries, uninterruptible power supplies, and numerous applications requiring stored energy solutions. Its segments include Energy Systems, Motive Power, and Specialty.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.